Speaker: 

Annie McDermott, PharmD, BCOP, Hematology/Oncology Clinical Pharmacist, Geisinger - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Pharmacy Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Define immunomodulatory drugs (IMiDs)​

• Present the teratogenicity risks of IMiDs ​

• Discuss Risk Evaluation and Mitigation Strategies (REMS) for IMiDs, including the Celgene program​

• Review Geisinger processes for prescribing and refills IMiDs

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Activity Director, Rajiv Panikkar, MD, Michele Long, MS, BSN, OCN, Jaime Weeder, CRNP, Christopher Kashi, PA-C and Caitlin McDonald, CPht, CVT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session

None.